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Abstract 
Background 
The MCF7 (ER+/HER2-), T47D (ER+/HER2-), BT474 (ER+/HER2+) and SKBR3 (ER-
/HER2+) breast cancer cell lines are widely used in breast cancer research as paradigms of 
the luminal and HER2 phenotypes. Although they have been subjected to cytogenetic 
analysis, their chromosomal abnormalities have not been carefully characterized, and their 
differential cytogenetic profiles have not yet been established. In addition, techniques such as 
comparative genomic hybridization (CGH), microarray-based CGH and multiplex ligation-
dependent probe amplification (MLPA) have described specific regions of gains, losses and 
amplifications of these cell lines; however, these techniques cannot detect balanced 
chromosomal rearrangements (e.g., translocations or inversions) or low frequency mosaicism. 
Results 
A range of 19 to 26 metaphases of the MCF7, T47D, BT474 and SKBR3 cell lines was 
studied using conventional (G-banding) and molecular cytogenetic techniques (multi-color 
fluorescence in situ hybridization, M-FISH). We detected previously unreported 
chromosomal changes and determined the content and frequency of chromosomal markers. 
MCF7 and T47D (ER+/HER2-) cells showed a less complex chromosomal make up, with 
more numerical than structural alterations, compared to BT474 and SKBR3 (HER2+) cells, 
which harbored the highest frequency of numerical and structural aberrations. Karyotype 
heterogeneity and clonality were determined by comparing all metaphases within and 
between the four cell lines by hierarchical clustering. The latter analysis identified five main 
clusters. One of these clusters was characterized by numerical chromosomal abnormalities 
common to all cell lines, and the other four clusters encompassed cell-specific chromosomal 
abnormalities. T47D and BT474 cells shared the most chromosomal abnormalities, some of 
which were shared with SKBR3 cells. MCF7 cells showed a chromosomal pattern that was 
markedly different from those of the other cell lines. 
Conclusions 
Our study provides a comprehensive and specific characterization of complex chromosomal 
aberrations of MCF7, T47D, BT474 and SKBR3 cell lines. 
The chromosomal pattern of ER+/HER2- cells is less complex than that of ER+/HER2+ and 
ER-/HER2+ cells. These chromosomal abnormalities could influence the biologic and 
pharmacologic response of cells. Finally, although gene expression profiling and aCGH 
studies have classified these four cell lines as luminal, our results suggest that they are 
heterogeneous at the cytogenetic level. 
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Background 
The MCF7, T47D, BT474 and SKBR3 breast cancer cell lines are commonly used in 
experimental studies of cellular function, and much of the current knowledge of molecular 
alterations in breast cancer has been obtained from these cell lines [1-4] 
Whole-genome studies using microarray expression analyses have identified distinct subtypes 
of breast carcinomas (the luminal, HER2+, and basal-like subtypes) based on the expression 
of approximately 500 genes (the so-called “intrinsic gene list”) [5-7]. These molecular 
subtypes have been approximated using immunohistochemical markers. In this way, estrogen 
(ER) and progesterone receptor (PR)+/HER2- tumors are classified as belonging to the 
luminal A molecular subtype, ER+/PR+/HER2+ tumors to the luminal B subtype, ER-/PR-
/HER2+ tumors to the HER2 subtype, and triple negative (ER-/PR-/HER2-) tumors to the 
basal-like carcinomas [8]. 
As determined by immunohistochemistry, the receptor profile classifies MCF7 and T47D 
cells (ER+/PR+/HER2-) as belonging to the luminal A subtype, BT474 cells 
(ER+/PR+/HER2+) as luminal B and SKBR3 cells (ER-/HER2+) as HER2 [9,10]. However, 
the RNA transcriptional profile determined by whole genome oligonucleotide microarrays 
[1,4,11] characterized all four-cell lines as luminal because of the expression of both ERα-
regulated genes (e.g., MYB, RET, EGR3, and TFF1) [1] and genes associated with luminal 
epithelial differentiation (e.g., GATA3 and FOXA1). 
Different works studies have studied assayed the DNA genetic profile of these cell lines using 
comparative genomic hybridization (CGH) and multiplex ligation-dependent probe 
amplification (MLPA) to describe many different copy number alterations [11-13]. With 
these techniques, however, balanced chromosome rearrangements (e.g., translocations or 
inversions) and low frequency mosaicism (< 30% abnormal cells) are not detectable. These 
chromosomal alterations may be assessed on metaphases using G-banding karyotype and 
multicolor fluorescence in situ hybridization (M-FISH) [2,12-16]. However, because both 
procedures are time consuming, they have been applied to only a small number of 
metaphases [2,12-17]. Thus, to our knowledge, a search for clonal chromosomal aberrations 
within each cell line [2,12-16] and a comprehensive comparison of the MCF7, T47D, BT474 
and SKBR3 cell lines from a cytogenetic perspective have not yet been performed. 
In the present study, we evaluated structural and numerical alterations on a large number of 
metaphases of MCF7, T47D, BT474 and SKBR3 breast cancer cell lines using a combination 
of G-banding and M-FISH. This allowed us to analyze cell clonality within each cell line and 
to thoroughly compare the cytogenetic of the cell lines by clustering analysis. 
Results 
Between 19 and 26 metaphases with good chromosome dispersion and morphology were 
analyzed for each cell line to define the structural and numerical alterations, and 100 
metaphases/cell line were analyzed to determine the level of ploidy. The rate and type of 
chromosomal abnormalities for each cell line are shown in Figure 1. 
Figure 1 Distribution of numerical and structural aberrations across the four breast 
cancer cell lines. der = derivative chromosome; del = deletion; dup = duplication; add = 
additional material of unknown origin; dic = dicentric chromosome. 
Cytogenetic profile and cluster analysis of MCF7 cells 
The cytogenetic analysis performed on 26 metaphases of MCF7 cells demonstrated a modal 
number hypertriploid to hypotetraploid (4n+/−) (76 to 88 chromosomes). Each chromosome 
harbored either a numerical or structural aberration, which accounted for 58 different 
rearrangements (31 numerical and 27 structural). Polyploidy was observed in 2% of the cells. 
Numerical alterations were present in all chromosomes; losses were more frequent than gains 
(Figure 1). Chromosomes 18 and 20 were nullisomic in 11.5% and 30.7% of the cells, 
respectively. Structural aberrations (translocations, duplications and deletions) were found in 
all chromosomes except 4, 5, 13, 14 and 18. 
A cluster analysis indicated that the types of chromosomal alterations were similar in the 26 
metaphases (horizontal dendrogram, Figure 2). Clustering by the frequency of the 
chromosomal aberration within a cell line produced 4 clusters (vertical dendrogram, Figure 
2). The first cluster (red bar) represented chromosomal alterations that were frequently 
present; chromosome 7 was the most affected by structural abnormalities. The second cluster 
(blue bar) represented alterations that were present in all metaphases, including chromosome 
losses and structural alterations of chromosomes 8 and 17. In particular, the loss of 
chromosomes 11, 18, 19 and 20 and the gain of chromosomes 7 and 17 were observed in all 
metaphases. 
Figure 2 Hierarchical cluster analysis of the presence or absence of chromosomal 
aberrations observed in 26 MCF7 metaphases. Each column refers to a metaphase (M) and 
each row to a chromosomal abnormality. Grey indicates the presence of each abnormality, 
and white indicates their absence. The cluster number is indicated by vertical color bars. 
Cluster 1: red bar, cluster 2: blue bar, cluster 3: green bar and cluster 4: purple bar. 
der(6)t(6;17;16)(q25;q21;?), der(8)t(8;15)(p11;?), der(16)t(8;16)(q?;q11.2), 
der(17)t(8;17)t(1;8) and der(17)t(17;19)(p11.1;p12) were present in all cells as a consequence 
of structural aberrations (Table 1 and Figure 3A and 3B). 
Table 1 G-Banding and M-FISH karyotypes of all breast cancer cell lines studied 
Cell line Karyotype 
MCF7 76 ~ 88 < 4n>,-X[11],-Xx2[8],-Xx3[4],der(X)t(X;15)(p11.2;q21)[16], 
der(X)t(X;15)(p11.2;q21)x2[3],der(X)dup(X)(q21qter)[5],-1[22]-1x2[2], 
der(1)t(1;21)t(9;21)[22],-2[13],-2x2[2],der(2)t(2;3)(q34;?)[19],-3[2], 
+3[17],del(3)(p14)[22],der(3)t(3;11)(p14;q13)[3],-4[12],-4x2[4], 
+5[2],-5[13],+6[9],+6x2[8],+6x3[4],add(6)(q27)[2],del(6)(q25)[4], 
del(6)(q25)x2[8], der(6)t(6;17;16)(q25;q21;?)[26], 
+7[26],der(7)t(1;7)(?;p15)[23],der(7)t(1;7)(?;p15)x2[2], 
del(7)(q11.2)[4],dup(7)(p13p15)[7],dup(7)(p13p15)x2[5],dup(7)(p13p15)x3[11],
dup(7)(p14p15)[5],dup(7)(p14p15)x2[2],der(7)t(7;7)(p15;?)[19], 
der(7)t(7;7)(p15;?)[2],-8[8], -8x2[12],der(8)t(8;15)(p11;?)[26],+9[3] 
−9[7],-9x2[2],der(9)t(8;9)(q13;p22)[22],-10[6],-10x2[10],-10x3[3], 
der(10)t(7;10)(?;p14)[9],der(10)t(7;10)(?;p14)x2[12],-11[14], 
−11x2[12],del(11)(q23)[2],-12[15],-12x2[4],+12[2], 
del(12)(p11.2)(5),del(12)(q24)[11],der(12)t(8,12)(q11;p11)[15], 
−13[12],-13x2[10],-13x3[2],-14[3],+14[14],-15[12],-15x2[10], 
−15x3[3],-16[3],+16[16],der(16)t(8;16)(q?;q11.2)[8],der(16)t(8;16)(q?;q11.2) 
x2[17]der(16)t(16;19)(q21;?)[2],+17[11],+17x2[10],+17x3[5],der(17)t(8;17)t(1;8
)[21],der(17)t(8;17)t(1;8)x2[5],der(17)t(17;19)(p11.1;p12)x2[17],-18[4], 
−18x2[14],-18x3[5],-18x4[3],-19[7],-19x2[15],-19x3[4], 
der(19)t(12;19)(q13;p13.3)[21],der(19)t(12;19)(q13;p13.3)x2[2],-20[2], 
−20x2[5],-20x3[11],-20x4[8],der(20)t(7;20)t(1;7)t(1;7)[21],+21[5],+21x2[2],-
21[14],-21x2[2],+22[12],+22x2[3],-22[3],-22x2[2],add(22)(q13)[4][cp26] 
T47D 57 ~ 66 < 3n>,X,-X[24],der(X)t(X;6)(q12;p11)[24],-1[19],-2[22], 
−3[5],del(3)(p11)[2],del(3)(p14)[2],del(3)(p21)[2],del(3)(q13)[6],del(3)(q22)[3], 
der(3)ins(3;5)(p14;q13q31)[2],der(3)del(3)(p13)del(3)(q13q25)ins(3;5)(q13;q13
q31)[2], 
−4[19],-5[2],+5[3],-6[17],+7[3],del(7)(p21)[3],del(7)(p13p14)[5], 
del(7)(p13p14)x2[10],del(7)(p13p15)[8],der(7)t(7;15)(q21;q13)[3],dup(7)(p13p1
4)[2],+8[12],der(8;14)(q10;q10)x2[24],-9[11],-9x2[9],-10[11],-
10x2[10],del(10)(p10)[3], 
der(10)t(3;10)(q?;q24)del(10)(p11.2)[14],der(10)t(3;10)(q?;q24)del(10)(p11.2)x2
[10],+11[9],+11x2[7],+11x3[2],der(11)t(11;17)(q23;q?)t(9;17)(q?12;?)[2],-
12[2],+12[6],+12x2[4], 
del(12)(p12)[6],del(12)(q24.1)[5],del(12)(q24.1)x2[3],der(12)del(12)(p12)del(12
)(q24)[4], 
der(12)t(12;13)(p12;q22)[10],der(12)t(12;16)(p11.2;?)[11],-13[16],-
13x2[4],+14[3],+14x2[13], 
+14x3[3],-15[6],-15x2[18],-16[2],der(16)t(1;16)(q12;q12)dup(1)(q21q43)[24], 
dic(9;17)t(9;17)(p12;p13)[13],dic(9;17)t(9;17)(p12;p13)x2[11],-18[17],-
18x2[4],-19[18], 
+20[9],+20x2[3],der(20)t(10;20)(q21;q13.3)[15],der(20)t(10;20)(q21;q13.3)x2[9
],der(20)del(20)(p11)t(10;20)(q21;q13.3)[10],+21[10],+21x2[6],-21[2], -
22[14][cp24] 
BT474 65 ~ 106 < 4n>,X,-X[9],-Xx2[5],-Xx3[4],der(X)t(X;17)(q13;q11q12)del(X)(p21) 
[9],der(X)t(X;18;X;12)[2],del(X)(q22)[14],-1[6],-1x2[2],+1[3],del(1)(p36.1)[6], 
-2[7],+2[7],der(2)t(1;2;7;20)(?;q31;?;?)[18],+3[12],-3[3],del(3)(p11.2)[7], 
del(3)(p14)[2],del(3)(q11.2)[6],del(3)(q11.2)x2[8],del(3)(q21)[4],del(3)(q13)[2], 
−4[8],-4x2[9],+4[2],-5[9],-5x2[9],+6[11],+6x3[3],-6[3], 
del(6)(q13)[3],del(6)(q21)[3],der(6)t(6;7)(q25;q31)[7],der(6)t(6;7)(q25;q31)x2[1
6],+7[4],+7x2[6],+7x3[9],+7x4[3],der(7)t(7;20)(p13;?)[5], 
der(7)t(1;7)(?;q11.2)[9], 
del(7)(q11.2)[7],del(7)(q11.2)x2[3],del(7)(q11.2)x3[3],der(7)t(7;14)(p13;p11.2)[
4],-8[10], -9[7],-9x2[4],-9x3[2],der(9)t(3;9)(q33;?)[3],+10[6],-10[5], 
der(10)t(10;16;19)(q25;?;?)[11],i(10)(q10)[4],+11[9],+11x2[2],-11[3], 
der(11)t(8;11)(q21.1;p15)[2],der(11)t(8;17)(q21.1;q11q12)t(11;17)(p15;q11q12)[
8],der(11)t(8;17)(q21.1;q11q12)t(11;17)(p15;q11q12)x2[12],der(11)t(8;17)(q21.
1;q11q12)t(11;17)(p15;q11q12)x3[3],der(11)t(11;17)(q?14;?)t(8;17)(?;q?11.2)[1
3], der(11)t(11;17)(q?14;q?11.2)[9],+12[8], 
+12x2[5],del(12)(p11.1)[2],der(12)t(5;12)(q23;q23)[17],der(12)t(5;12)(q23;q23)
x2[2],der(12)del(12)(p12)del(12)(q24)[3],-13[7],+13[6],+13x2[3],+13x4[2], 
der(13)t(13;17)(q10;q11q12)t(13;17)(q10;q11q12) 
[8],der(13)t(13;17)(q10;q11q12)t(13;17)(q10;q11q12)x2[12],+14[11], 
+14x2[3],+14x3[2],der(14)t(14;1;14)(q31;?;?)[6],der(14)t(14;1;14)(q31;?;?)x2[5]
, 
der(14)t(14;1;14)(q31;?;?)x3[9],der(14)t(14;1;14)(q31;?;?)x4[3], 
add(14)(p11.2)[2],der(14;14)(q10;q10)[3],der(14;14)(q10;q10)x2[16],-15[6],-
15x2[9], -15x3[6],+16[7],+16x2[6],+16x3[3],-
16[2],der(16)t(X;16)(q22;q24)[10], 
+17[16], der(17)t(6;17)(?;p13)t(15;17)(q11.2;q25)[22],-18[10],-18x2[4],-
18x3[2],-19[6], 
−19x2[5],+19[5],-20[6],-20x2[6],+20[3],+20x3[2],der(20)t(19;20)(?;q10)[4], 
der(20)t(19;20)(?;q10)x2[5],+21[2],-21x2[11],-21x3[3],-22[2],-22x2[5],-
22x3[2],-22x4[12], 
der(22)t(16;22)(q12;p11.2)[5][cp23] 
SKBR3 76 ~ 83 < 4n>,XXX,-X[19],der(X)t(X;17)(q21;q?21)[15], 
der(X)t(X;8;17)(q13;q?21;?)[6],+1[8],+1x3[5],add(1)(p36.3)[4], 
del(1)(p13)[11],del(1)(p13)x2[6],del(1)(p34)[4],del(1)(p22)[9],del(1)(p36.1)[2], 
der(1)t(1;4)(q12;q12)[6],-2[6],-2x2[8],-2x3[3],der(2)t(2;6)(p13;?)[5],-3[10],-
3x2[6],-4[8], 
−4x2[8],-4x3[3],der(4;14)t(4;14)(p11;p11.1)[3],-5[8], 
−5x2[8],-5x3[2],der(5)ins(5;15)(p13;q12q22)[6],-6[4],-6x2[12], 
−6x3[2],der(6)t(6;14;17)(q21;?;q11q12)del(6)(p23)[8],+7x2[8],+7x3[10], 
del(7)(q22)[12],del(7)(q32)[3],dup(7)(p14p15)[2],-8[6],+8[8], 
der(8)t(8;21)(?;?)t(8;21)(p23;?)t(8;21)(q24;?)[11],der(8)t(8;21)(?;?)t(8;21)(p23;?
)t(8;21) 
(q24;?)x2[8],der(8)dup(8)(?)t(8;8)(?;p23)t(8;17)(q24;?)t(11;17)(?;?)[4], 
 der(8;14)t(8;14)(p11.1;p11.1)[15],-9[9],-9x2[7],-10[4],-10x2[13],-
10x3[2],+11[2],-11[7], 
add(11)(p15)[4],add(11)(q25)[2],-12[6],-
12x2[5],+12[3],der(12)t(11;12)(p?;p12)[4], 
der(12)t(5;12)(q23;q23)[10],der(12)t(5;12)(q23;q23)x2[4],-13[6],-13x2[8], 
 −13x3[3],der(13;13)(q11.2;q11.2)[16],-14[6],-14x2[4], 
 der(14;14)(q11.2;q11.2)[18],-15[10],-15x2[7], dic(15;21)(p11.1;p11.1)[3], 
+16[4],-16[7],-
17[3],+17[9],der(17;17)t(17;17)(q25;?)dup(17)(q22q25)t(17;20)(?;?)[5], 
 der(17;17)t(17;17)(q25;?)dup(17)(q22q25)t(17;20)(?;?)x2[7], 
der(17;17)t(17;17)(q25;?)dup(17)(q22q25)t(17;20)(?;?)x3[7],del(17)(p11.2)[7], 
 der(17)t(8;17)(q12;?)dup(17)(?)[19],der(17)t(8;17)(?;q25)dup(17) 
 (q22q25)[5],der(17)t(8;17)(?;q25)dup(17)(q22q25)x2[2],der(17)t(8;13;14;17;21)
(?;q?;q?;q11q12;?)[8],der(17)t(3;8;13;17;20)(?;?;q12;?p;?)[12],der(17)t(3;8;13;1
7;20)(?;?;q12;?p;?)x2[2],-18[3],-18x2[11],-
18x3[5],der(18)t(18;22)(p11.2;?)[12],-19[4],-19x2[7],-20[8],-20x2[4], 
−20x3[7],-21[6],-21x2[3],-22[9],-
22x2[4],+22[2],der(22)t(19,22)(q?;q13)[5][cp19] 
The number of metaphases analyzed is reported in brackets at the end of each karyotype. 
Additionally, the frequency of each rearrangement identified is described in brackets. 
Figure 3 G-Banding and molecular cytogenetic results of four breast cancer cell lines. 
A-B) G-banded and M-FISH karyotype of a representative metaphase of MCF7 cells. C-D) 
G-banded and M-FISH karyotype of a representative metaphase of T47D cells. E-F) G-
banded and M-FISH karyotype of a representative metaphase of BT474 cells. G-H) G-
banded and M-FISH karyotype of a representative metaphase of SKBR3 cells. 
Less frequent alterations (mainly numerical) constituted cluster 3 (green bar), and very rare 
alterations (ranging from 0 in metaphases M_21 and M_26 to 5 in metaphases M_13 and 
M_22) constituted cluster 4 (purple bar). 
Cytogenetic profile and cluster analysis of T47D cells 
In the T47D cells, 24 metaphases were examined. The modal number was near triploidy 
(3n+/−) (57 and 66 chromosomes). T47D cells had 52 different chromosomal alterations (27 
numerical and 25 structural) (Figure 1). Polyploidy was observed in 4% of the analyzed cells, 
and numerical chromosomal alterations were present in all chromosomes. Structural 
aberrations (deletions, translocations, and duplications) were found in all chromosomes 
except 2, 4, 18, 19, 21 and 22. 
As in the MCF7 cells, the types of chromosomal alterations were almost homogeneously 
distributed among the 24 metaphases of T47D cells, as demonstrated by hierarchical 
clustering (horizontal dendrogram, Figure 4). When the frequency of chromosomal 
alterations was analyzed, 3 clusters were identified (vertical dendrogram): the first and largest 
cluster (red bar) was formed by common numerical alterations with a prevalence of losses. 
The rare structural aberrations present in this cluster primarily involved chromosome 12. In 
the second cluster (the smallest, blue bar), der(X)t(X;6)(q12;p11), der(8;14)(q10;q10), 
der(10)t(3;10)(q?;q24)del(10)(p11.2), der(16)t(1;16)(q12;q12)dup(1)(q21q43), 
dic(9;17)t(9;17)(p12;p13) and der(20)t(10;20)(q21;q13.3) were present in all metaphases as 
the result of translocations, together with the loss of chromosomes 15 and X (Table 1 and 
Figure 3C and 3D). Cluster 3 (green bar) grouped rare abnormalities (ranging from zero in 
metaphases M_17 and M_21 to 4 in metaphases M_11 and M_10), most of which were 
structural (Figure 4). 
Figure 4 Hierarchical cluster analysis of the presence or absence of chromosomal 
aberrations observed in 24 T47D metaphases. Each column refers to a metaphase (M) and 
each row to a chromosomal abnormality. Grey indicates the presence of each abnormality, 
and white indicates their absence. The cluster number is indicated by vertical color bars. 
Cluster 1: red bar, cluster 2: blue bar and cluster 3: green bar. 
Cytogenetic profile and cluster analysis of BT474 cells 
For BT474 cells, 23 metaphases were examined. These cells showed the highest frequency of 
numerical and complex structural aberrations of all cell lines analyzed. BT474 cells had a 
modal number near tetraploidy (4n+/−) (from 65 to 106 chromosomes) and showed 35 
numerical and 36 structural aberrations (Figure 1). Polyploidy was not present. 
As in the other cell lines, cluster analysis demonstrated nearly homogeneous chromosome 
alterations in all metaphases (horizontal dendrogram, Figure 5). Isochromosomes, deletions 
and derivatives were frequent (Table 1 and Figure 3E and 3F). Numerical alterations were 
also observed in all chromosomes, with losses being more frequent than gains. Losses of 
chromosomes X, 15 and 22 were observed in 78%, 91% and 91% of metaphases, 
respectively, while gain of chromosome 7 was identified in 96% of cells. 
Figure 5 Hierarchical cluster analysis of the presence or absence of chromosomal 
aberrations observed in 23 BT474 metaphases. Each column refers to a metaphase (M) and 
each row to a chromosomal abnormality. Grey indicates the presence of each abnormality, 
and white indicates their absence. The cluster number is indicated by vertical color bars. 
Cluster 1: red bar and cluster 2: blue bar. 
The frequency of alterations within the cell line produced 2 clusters (vertical dendrogram): in 
cluster 1 (red bar), both numerical and structural alterations were present in almost all cells. 
Only three structural alterations were reproduced in all metaphases, namely 
der(6)t(6;7)(q25;q31), der(11)t(8;17;11)(q21.1;?;p15) and der(14;1;14)(q31;?;?) (Table 1 and 
Figure 3E and 3F). Cluster 2 (blue bar) included sporadic aberrations with a minimum of 3 
such alterations observed in metaphase M_22 (Figure 5). 
Cytogenetic profile and cluster analysis of SKBR3 cells 
In this cell line, 19 metaphases were examined. SKBR3 cells showed a hypertriploid to 
hypotetraploid (4n+/−) (76 to 83 chromosomes) karyotype. Polyploidy was observed in 19% 
of all cells. SKBR3 cells had 29 numerical and 33 structural aberrations (Figure 1). 
Numerical chromosomal alterations were observed in all chromosomes. Structural aberrations 
(translocations, deletions, and duplications) were found in all chromosomes except 3, 9, 10 
and 16 (Table 1 and Figure 3G and 3H). 
In comparison to other cell lines, hierarchical clustering showed similarities of chromosomal 
alterations among the 19 metaphases (horizontal dendrogram, Figure 6). Clustering by the 
frequency of chromosomal alterations defined 3 clusters (Figure 6). The largest cluster 
(cluster 1, red bar) was formed by sporadic aberrations, with structural aberrations being 
prevalent. Cluster 2 (blue bar) included frequent rearrangements, with more numerical than 
structural aberrations. The smallest group (cluster 3, green bar) contained chromosomal 
abnormalities that were present in all cells, both numerical, such as monosomies of 
chromosomes X, 4, 10, 18 and 20, and structural, such as those on chromosomes 8, 17 and 1. 
Figure 6 Hierarchical cluster analysis of the presence or absence of chromosomal 
aberrations observed in 19 SKBR3 metaphases. Each column refers to a metaphase (M) 
and each row to a chromosomal abnormality. Grey indicates the presence of each 
abnormality, and white indicates their absence. The cluster number is indicated by vertical 
color bars. Cluster 1: red bar, cluster 2: blue bar and cluster 3: green bar. 
Comparison of the four cell lines 
Using hierarchical clustering, we identified five major clusters (Figure 7). One cluster was 
characterized mainly by numerical chromosome abnormalities (18 losses and 7 gains) that 
were common to the four cell lines. Only two structural alterations, namely 
der(14;14)(q10;q10) and der(12)t(5;12)(q23;q23), were common to HER2+ cells. The other 
clusters, however, encompassed cell type-specific abnormalities that were primarily structural 
(Figure 7). This analysis revealed greater similarity between T47D and BT474 cells and some 
similarity between these two cell lines and the SKBR3 cell line. MCF7 cells demonstrated a 
chromosome pattern that was markedly different from those of the other lines (Figure 8). 
Figure 7 Hierarchical cluster analysis of the percentage of chromosomal aberrations 
observed in four breast cancer cell lines. Clustering stratifies cell lines into five groups. 
The first cluster was characterized by the presence of numerical chromosomal abnormalities 
(aneuploidies) that were common to the four cell lines (ER+, ER-, HER2+, HER2-). The 
other clusters comprised cell type-specific chromosomal abnormalities. The gradient color 
indicates percentage of chromosomal abnormalities present in each cell line. 
Figure 8 Cluster dendrogram derived from cytogenetic analysis of the four breast 
cancer cell lines. These analyses confirmed the greater similarities between T47D and 
BT474 cell lines and between these two cell lines and the SKBR3. MCF7 cells demonstrate a 
chromosomal pattern that was markedly different from those of previous cells. 
Discussion 
The MCF7 (ER+/HER2-), T47D (ER+/HER2-), BT474 (ER+/HER2+) and SKBR3 (ER-
/HER2+) cell lines are widely used in breast cancer research as paradigms of the luminal and 
HER2 immunophenotypes [9,10]. Although classical cytogenetic analysis is time consuming 
and lacks the resolution of molecular techniques, it is the best tool for obtaining an overall 
picture of the types and frequency of chromosome changes. The results obtained using G-
Banding and M-FISH analyses of a large number of metaphases allowed us to acquire a 
thorough insight of the type and frequency of chromosome alterations in the MCF7, T47D, 
BT474 and SKBR3 cell lines and to detect previously unreported chromosome alterations 
(Table 2). 
Table 2 Comparison of selected chromosomal aberrations detected in MCF7, T47D, BT474 and SKBR3 cell lines in previous studies and in our G-banding and M-
FISH results 
Cell line ATCC National Center for Biotechnology 
Formation NCBI[18] 
Gasparini, et al. 
2010[15] 
Davidson, et al. 2000 [14] G-banding and M-FISH present study 
MCF7 NR NR dup(X)(?;qter) der(1)t(X;1) der(X)dup(X)(q21qter) 
 NR NR NR NR der(6)t(6;17;16)(q25;q21;?) 
 NR der(17)t(17;20)(q25;?)t(1;20)t(1;3or7) NR der(?)t(11;1;17;19;17) der(17)t(17;19)(p11.1;p12) 
 NR NR NR der(?)t(17;1;19;17;20) der(17)t(8;17)t(1;8) 
T47D der(8)t(8;14) der(8)t(8;14)(p21;q21) _ der(8)t(8;14) der(8;14)(q10;q10) 
 der(9)t(9;17) der(9)t(9;17)(p12;q?11) _ NR dic(9;17)t(9;17)(p12;p13) 
 der(10)t(10;20) der(20)t(10;20)(q21;q13) _ NR der(20)t(10;20)(q21;q13.3) 
BT474 der(6)t(6;7)(q21;q21) _ der(6)t(6;7)(q25;?) _ der(6)t(6;7)(q25;q31) 
 NR _ der(11)t(8;11;??)(?;p15;?) _ der(11)t(8;17;11)(q21.1;?;p15) 
 NR _ NR _ der(11)t(11;17)(q?14;q?11.2) 
 i(13q) _ der(13;13)(q10;q10) _ der(13)t(13;17;13)(q10;?;q10) 
 der(14)t(14;?)(q32,?) _ der(14)t(1;14;X)(?;q31;?) _ der(14)t(14;1;14)(q31;?;?) 
SKBR3 NR _ NR der(8)t(8;21) der(8)t(8;21)(?;?)t(8;21)(p23;?)t(8;21)(q24;?) 
 NR _ NR NR der(8)dup(8)(?)t(8;8)(?;p23)t(8;17)(q24;?)t(11;17)(?;?) 
 NR _ NR der(?)t(8;14) der(8;14)t(8;14)(p11.1;p11.1) 
 NR _ NR NR der(17)t(8;17)(q12;?)dup(17)(?) 
 NR _ NR der(?)t(20;19;8;17) der(17;17)t(17;17)(q25;?)dup(17)(q22q25)t(17;20)(?;?) 
 NR _ NR der(8?)t(13;3;8;3;8;13) der(17)t(8;13;14;17;21)(?;q?;q?;q11q12;?) 
 NR _ NR der(?)t(20;3;8;17;19;8;3;13) der(17)t(3;8;13;17;20)(?;?;q12;?p;?) 
 NR _ NR NR der(17)t(8;17)(?;q25)dup(17)(q22q25) 
 NR _ NR der(?)t(19;22) der(22)t(19,22)(q?;q13) 
Abbreviations: NR, not reported. Dashes indicate that no information was available. 
Cluster analysis excluded the presence of cell clones within each cell line because the same 
abnormalities were homogenously observed in all metaphases. Conversely, within the same 
cell line, the frequency of each chromosome alteration was variable and defined different 
clusters. Finally, a comparison of these four cell lines using cluster analysis showed that they 
shared up to 5 numerical aberrations in more than 50% of the metaphases (−2, -4, -15, -18, -
X) and that the chromosomal structural alterations were cell-type specific, with the exception 
of two derivative chromosomes that were shared by the BT474 and SKBR3 HER2+ cell 
lines. 
The HER2+ cell lines BT474 and SKBR3 showed the highest frequency of numerical and 
structural aberrations in comparison with the HER2- cell lines MCF7 and T47D. Polyploidy, 
which was more frequent in HER2+ than in HER2- cells, has been correlated with short 
survival, drug resistance and metastasis [19]. In addition, complex chromosome alterations 
affecting chromosomes 8, 11, and 17 were frequently observed in HER2+ cells. These 
chromosomes contain genes that are commonly involved in the invasion, metastasis and 
pathogenesis of breast cancer, including c-MYC on 8q24; HRAS, CD151, CTSD on 11p15; 
CCND1 on 11q13 [20-24]; and TOP2A on 17q21. Moreover, in HER2+ cells and carcinomas, 
rearrangements of chromosome 17 are more frequent than is polysomy. Pathologists must 
consider this observation for when diagnosing the HER2 amplification in interphase nuclei of 
breast carcinomas, which uses a ratio between HER2 copies and chromosome 17 centromere 
signals [25,26]. 
Among ER + cells, MCF7 cells are cytogenetically different than both T47D (ER+/HER2-) 
and BT474 (ER+/HER2+) cells and are characterized by a specific subset of complex 
structural alterations, which are listed in the cluster analysis comparison of the four cell lines 
(Figure 7). In particular, chromosome 7 was frequently structurally and numerically affected, 
and polysomy of chromosome 7 was observed in all metaphases. This finding has been 
closely associated with lymph node metastasis and prognosis in breast cancer patients [27]. 
One may speculate that the differences observed in the pattern of chromosomal aberrations 
between the MCF7 and T47D cell lines could partly explain the differences in the profile of 
protein expression that was recently identified in these cells [28]. Proteomic studies have 
revealed that a high number (at least 164) of proteins (including proteins involved in the 
regulation of breast cancer cell growth) are differentially expressed by T47D and MCF7 cells 
[28]. For example, of the proteins that are principally involved in cell proliferation and 
apoptosis and are upregulated in MCF7 cells, the Chromobox protein homolog 3 and the 
Cytochrome c-releasing factor 21 are encoded by genes mapping to chromosome 7, which is 
typically polysomic in MCF7 cells, as reported above. The differences in the karyotype 
should be considered when designing related experimental studies, such as those that analyze 
the effect of gene transfection. It is possible that complex chromosome alterations may alter 
the results. MCF7 cells, which differ greatly from the BT474 and SKBR3 (HER2+) cells, are 
frequently used to study the effect of HER2 transfection [29-31]; however, they may not 
represent the best substrate. Conversely, T47D cells (ER+/HER2-) and BT474 cells share 
similarities in the chromosome profile, and both have some chromosomal similarities with 
SKBR3 cells. For example, T47D and BT474 cells share numerical alterations, such as losses 
of chromosome 6 and gains of chromosomes 11 and 20, but they have no structural 
abnormalities in common. 
One may hypothesize that the earliest genetic event may be aneuploidy, followed by 
structural alterations [32,33]. Aneuploidy is one of the most common properties of cancer 
[34]. In addition, numerical abnormalities have been observed more frequently in primary 
cancers, while structural alterations and amplifications were more commonly observed in 
metastatic breast cancer [33]. These structural alterations may lead to the deregulated 
expression of genes, such as a loss of tumor suppressor genes, the activation of oncogenes 
and the formation of fusion proteins with enhanced or aberrant transcriptional activity. For 
instance, some of the genes upregulated in HER2+ cell lines [35] reside on chromosomes 5, 
6, 10, 19, and 20, which were reported to be polysomic in BT474 cells in the present study 
(Additional file 1: Table S1). 
Conclusions 
In conclusion, by using both conventional and molecular karyotyping, our work provides a 
comprehensive and specific characterization of complex chromosomal aberrations for MCF7, 
T47D, BT474 and SKBR3 cell lines, thus providing important information for experimental 
studies. These cell lines serve as models for investigating the molecular biology of breast 
cancer; therefore, it may be essential to consider the potential influence of these chromosomal 
alterations when interpreting biological data. 
Methods 
Cell lines 
The human breast cancer cell lines MCF7 (ER+/HER2-), T47D (ER+/HER2-), BT474 
(ER+/HER2+) and SKBR3 (ER-/HER2+) were obtained from the American Type Culture 
Collection (ATCC, Manassas, VA, USA) in March 2010. Short tandem repeat (STR) analysis 
is routinely performed by ATCC during both accessioning and culture replenishment to avoid 
distributing misidentified cell lines to the scientific community. When received by our lab, 
these cell lines were expanded, and 3 vials were immediately frozen. Cells obtained from 
these stocks were used for the experiments. The cell lines were further authenticated based on 
the expression of epithelial markers (keratins 8 and 18) and the presence of specific receptors 
(ERα, PGR, HER2, AR and EGFR) using quantitative PCR (qPCR) and 
immunohistochemical analysis. The expression status of ERα and HER2 was further 
confirmed by western blot. 
MCF7, T47D, and SKBR3 cells were cultured in RPMI 1640 medium (Sigma, St. Louis, 
MO, USA), while BT474 cells were cultured in DMEM medium (Sigma). Culture media 
were supplemented with 10% fetal bovine serum (FBS) (Sigma), antibiotic-antimycotic 
solution (1X) (Sigma) and L-glutamine (2 mM) (Invitrogen GmbH, Karlsruhe, Germany). 
The cultures were maintained in an incubator at 37ºC and 5% CO2 and were determined to be 
free of contamination with mycoplasma by PCR assay. Cell line characteristics and culture 
conditions are further described in supplemental information (Additional file 2: Table S2). 
Metaphase spreads and G-Banding 
Metaphases were obtained using standardized harvesting protocols for conventional and 
molecular cytogenetic analysis (M-FISH). Briefly, colcemid solution (0.03 µg/ml) (Sigma) 
was added to cultures 2.5 hours (h) before cell harvesting; cells were then treated with 
hypotonic solution, fixed three times with Carnoy’s fixative (3:1 methanol to acetic acid) and 
spread on glass. 
Glass slides were baked at 70°C for 24 h, incubated in HCl and placed in 2xSSC buffer 
before treatment with Wright’s stain. Image acquisition and subsequent karyotyping of 
metaphases were performed using a Nikon microscope with the cytogenetic software 
CytoVision System (Applied Imaging, Santa Clara, CA, USA). Chromosome aberrations 
were described according to the International System for Human Cytogenetic Nomenclature 
(ISCN) 2013 [36] 
Multi-color fISH (M-FISH) 
M-FISH was performed with the aim of identifying complex chromosomal rearrangements. 
The probe cocktail containing 24 differentially labeled chromosome-specific painting probes 
(24xCyte kit MetaSystems, Altlussheim, Germany) was denatured and hybridized to 
denatured tumor metaphase chromosomes according to the manufacturer’s protocol for the 
Human Multicolor FISH kit (MetaSystems). Briefly, the slides were incubated at 70°C in 
saline solution (2xSSC), denatured in NaOH, dehydrated in ethanol series, air-dried, covered 
with 10 µl of probe cocktail (denatured) and hybridized for two days at 37°C. The slides were 
then washed with post-hybridization buffers, dehydrated in ethanol series and counter-stained 
with 10 µl of DAPI/antifade. The signal detection and analysis of subsequent metaphases 
used the Metafer system and Metasytems’ ISIS software (software for spectral karyotypes). 
Hierarchical clustering 
The first cluster analysis was performed to assess the chromosomal heterogeneity of each cell 
line by considering the type and frequency of chromosomal alterations within metaphases. 
Each alteration was computed as present or absent within the karyotype of different 
metaphases. In the second cluster analysis, the frequency (%) of each chromosomal alteration 
was compared among the four cell lines. Hierarchical clustering was performed using 
package gplots from the Bioconductor project (http://www.bioconductor.org) for the R 
statistical language. A Euclidean distance was used to calculate the matrix of distances, and 
clusters were built using Ward’s method. 
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